28.13
+0.0483(+0.17%)
Currency In USD
| Previous Close | 28.13 |
| Open | 28.6 |
| Day High | 28.6 |
| Day Low | 27.49 |
| 52-Week High | 32.63 |
| 52-Week Low | 4.66 |
| Volume | 42,744 |
| Average Volume | 298,189 |
| Market Cap | 1.26B |
| PE | -4.08 |
| EPS | -6.9 |
| Moving Average 50 Days | 27 |
| Moving Average 200 Days | 18.87 |
| Change | 0.05 |
If you invested $1000 in Septerna, Inc. (SEPN) since IPO date, it would be worth $1,314.49 as of March 04, 2026 at a share price of $28.13. Whereas If you bought $1000 worth of Septerna, Inc. (SEPN) shares 1 year ago, it would be worth $4,566.56 as of March 04, 2026 at a share price of $28.13.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Septerna Announces Positive Phase 1 Data for SEP-631, an Oral MRGPRX2 NAM for the Treatment of Mast Cell-Driven Diseases, and Outlines Initial Phase 2 Development Strategy
GlobeNewswire Inc.
Mar 01, 2026 2:45 PM GMT
SEP-631 Demonstrated Robust, Dose-Dependent Inhibition of Icatibant-Induced Skin Wheal Formation, with Complete Inhibition Observed at Doses as Low as 10 mg Once-Daily Well-Tolerated Across All Doses Studied with an Adverse Event Profile Comparable
Septerna to Present at TD Cowen 46th Annual Health Care Conference
GlobeNewswire Inc.
Feb 24, 2026 1:00 PM GMT
SOUTH SAN FRANCISCO, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, announced that Jeffrey Finer, M.D., Ph.D
Septerna Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Feb 10, 2026 9:05 PM GMT
SOUTH SAN FRANCISCO, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, announced today that on February 6, 2026,